Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
Edgar Carnero Contentti, Jorge Correale
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3473-3490
Open Access | Times Cited: 12

Showing 12 citing articles:

BTK signaling—a crucial link in the pathophysiology of chronic spontaneous urticaria
Jonathan A. Bernstein, Marcus Maurer, Sarbjit S. Saini
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 5, pp. 1229-1240
Open Access | Times Cited: 19
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells
Federica Galota, Simone Marcheselli, Sara De Biasi, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 606-606
Open Access
Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases
Mirre De Bondt, Janne Renders, Sofie Struyf, et al.
Autoimmunity Reviews (2024) Vol. 23, Iss. 5, pp. 103532-103532
Closed Access | Times Cited: 3
Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
O. А. Shulga, A.S. Romaniuk, O.G. Kotsiuba
Postępy Psychiatrii i Neurologii (2023) Vol. 32, Iss. 1, pp. 23-30
Open Access | Times Cited: 8
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis
Michael Hecker, Niklas Frahm, Uwe K. Zettl
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 3-3
Open Access | Times Cited: 6
Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis
Barbara Nuesslein‐Hildesheim, Enrico Ferrero, Cindy Schmid, et al.
Journal of Neuroinflammation (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 5
The role of Bruton's tyrosine kinase in pathogenesis of chronic spontaneous urticaria and the prospects for the use of new treatment.
E S Fedenko, O G Elisyutina, N I Ilina
Russian Journal of Allergy (2024) Vol. 21, Iss. 2, pp. 265-282
Open Access | Times Cited: 1
Unraveling the Role of the Glycogen Synthase Kinase-3β, Bruton’s Tyrosine Kinase, and Sphingosine 1 Phosphate Pathways in Multiple Sclerosis
Rupali Mohite, Sankalp Gharat, Gaurav Doshi
Endocrine Metabolic & Immune Disorders - Drug Targets (2024) Vol. 24, Iss. 10, pp. 1131-1145
Closed Access
Standardisation of MRI usage in
Manuela Vaněčková, Dominika Šťastná, Pavel Ryška, et al.
(2024) Vol. 78, Iss. 2, pp. 101-114
Open Access
Suppression of Multiple Sclerosis by Ultraviolet Light
Lori A. Plum, Hector DeLuca
Medical Research Archives (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective
Holger Scheible, Hanno Schieferstein, Ralf Schmidt, et al.
Xenobiotica (2023) Vol. 53, Iss. 8-9, pp. 547-558
Open Access | Times Cited: 1
Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases
Pei Lin, Dandan Zhang, Jun Lin
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 28, pp. 2609-2620
Closed Access
Page 1

Scroll to top